<p>ICU Medical, Inc.（納斯達克代碼：ICUI - 獲取免費報告）在目前覆蓋該公司的五家研究機構中獲得了 “買入” 的平均推薦，Marketbeat.com 報道。一位研究分析師對該股票給予了賣出評級，兩位給予了買入評級，兩位給予了強烈買入評級。在過去一年中更新了對該股票覆蓋的經紀公司中，12 個月的平均目標價為 169.00 美元。</p>
<p>一些股票分析師最近對 ICUI 股票發佈了報告。傑富瑞金融集團在週四的報告中將 ICU Medical 的評級上調至 “強烈買入”。派珀·桑德勒在 4 月 17 日的報告中將 ICU Medical 的目標價從 178.00 美元下調至 163.00 美元，並對該股票給予了 “超配” 評級。華爾街 Zen 在 4 月 18 日的報告中將 ICU Medical 的評級從 “買入” 下調至 “持有”。KeyCorp 在 4 月 27 日的報告中將 ICU Medical 的目標價從 180.00 美元下調至 164.00 美元，並對該股票給予了 “超配” 評級。最後，Weiss Ratings 在 1 月 22 日的報告中重申了對 ICU Medical 股票的 “賣出（d-）” 評級。</p>
<p><strong>獲取我們關於 ICUI 的最新報告</strong></p>
<h2>機構資金流入和流出</h2>
<p>機構投資者和對沖基金最近修改了對該公司的持股。Bryce Point Capital LLC 在第三季度購買了 ICU Medical 股票的新頭寸，價值 586,000 美元。Inscription Capital LLC 在第三季度將其在 ICU Medical 的持股增加了 407.9%。Inscription Capital LLC 現在擁有 8,365 股該醫療器械供應商的股票，價值 1,003,000 美元，在上個季度又購買了 6,718 股。Federated Hermes Inc.在第三季度將其在 ICU Medical 的持股增加了 56.5%。Federated Hermes Inc.現在擁有 290,292 股該醫療器械供應商的股票，價值 34,823,000 美元，在上個季度又購買了 104,798 股。Emerald Mutual Fund Advisers Trust 在第三季度購買了 ICU Medical 股票的新頭寸，價值 1,096,000 美元。最後，施羅德投資管理集團在第三季度將其在 ICU Medical 的持股增加了 25.2%。施羅德投資管理集團現在擁有 796,704 股該醫療器械供應商的股票，價值 93,246,000 美元，在上個季度又購買了 160,380 股。對沖基金和其他機構投資者持有該公司 96.10% 的股票。</p>
<h2>ICU Medical 的關鍵新聞</h2>
<p>以下是本週影響 ICU Medical 的關鍵新聞：</p>
<ul>
<li>積極情緒：第一季度收益超出預期——ICU 報告每股收益 1.97 美元，超過 1.78 美元的共識預期，收入為 5.258 億美元，超出預期，顯示出運營上的超出，通常會支持股票。ICU Medical（ICUI）第一季度收益和收入超出預期</li>
<li>積極情緒：2026 財年指引略微高於市場預期（每股收益指引為 7.75–8.45 美元，而共識約為 7.74），這降低了未來收益的下行風險，並支持估值擴張。ICU Medical 公佈 2026 年第一季度業績</li>
<li>積極情緒：分析師支持——傑富瑞將 ICU 評級上調至 “強烈買入”，派珀·桑德勒重申其買入評級，帶來了額外的買方關注，可能會提升股票。傑富瑞升級/覆蓋説明派珀·桑德勒重申買入</li>
<li>中性情緒：投資者材料可用——公司發佈了其幻燈片和收益演示，便於深入瞭解細分趨勢和利潤驅動因素，但本身並不是立即的價格催化劑。收益電話會議演示</li>
<li>消極情緒：收入和利潤壓力——收入同比下降約 12-14%，報告的淨利潤率仍然非常薄弱，這引發了對增長軌跡和收益質量的質疑，儘管每股收益超出預期。季度業績和會議記錄</li>
</ul>
<h2>ICU Medical 股票表現</h2>
<p>納斯達克 ICUI 的股票在週五開盤價為 123.07 美元。該公司的速動比率為 1.15，流動比率為 2.39，債務與股本比率為 0.60。該股票的市值為 30.8 億美元，市盈率為 6,156.58，PEG 比率為 1.72，貝塔值為 0.74。該股票的 50 日簡單移動平均線為 128.93 美元，200 日簡單移動平均線為 138.35 美元。ICU Medical 的 52 周低點為 107.00 美元，52 周高點為 160.29 美元。</p>
<p>ICU Medical（納斯達克代碼：ICUI - 獲取免費報告）最後一次發佈其收益結果是在 2 月 19 日，星期四。該醫療器械供應商報告本季度每股收益（EPS）為 1.91 美元，超過分析師共識預期的 1.68 美元，超出 0.23 美元。該公司本季度的收入為 5.3594 億美元，而分析師的預期為 5.4120 億美元。ICU Medical 的股本回報率為 7.33%，淨利潤率為 0.03%。該公司的季度收入同比下降 14.1%。在前一年同期，該公司發佈的每股收益為 2.11 美元。ICU Medical 已將其 2026 財年的指引設定為每股收益 7.750-8.450 美元。作為一個整體，賣方分析師預測 ICU Medical 在當前財年將發佈每股收益 6.31 美元。</p>
<h2>ICU Medical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>ICU Medical, Inc 及其子公司開發、製造和銷售用於輸液治療、血管通路和生命監護應用的醫療設備。其輸液治療產品包括 MicroClave、MicroClave Clear 和 NanoClave 品牌的無針產品；Neutron 導管通暢設備；ChemoClave 和 ChemoLock 封閉系統轉移設備，用於限制有害藥物或蒸汽濃度的逸出，阻止環境污染物進入系統，並消除針刺傷害的風險；Tego 無針連接器；Deltec GRIPPER 非穿刺針用於門靜脈通路；以及 ClearGuard、SwabCap 和 SwabTip 消毒蓋。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票超過 ICU Medical</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUNVSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUNVSQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何關於此故事的問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 ICU Medical 嗎？</h2>
<p>在考慮 ICU Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 ICU Medical 並不在名單上。</p>
<p>雖然 ICU Medical 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ICU醫療

<p>ICU Medical, Inc.（納斯達克代碼：ICUI）獲得了五家研究公司的平均 “買入” 評級。一位分析師將其評為賣出，另外兩位評為買入，另外兩位評為強力買入。12 個月的平均目標價為 169 美元。最近的報告顯示分析師意見不一，Jefferies 將評級上調至 “強力買入”，而 Piper Sandler 則下調了目標價。機構投資者持有 96.10% 的股份。儘管第一季度的盈利超出預期，但收入同比下降了 12-14%，引發了對增長和利潤率的擔憂</p>

<p>ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) has been given an average recommendation of &#34;Buy&#34; by the five research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $169.00.</p>
<div class="lb-trans"><p>ICU Medical, Inc.（納斯達克代碼：ICUI - 獲取免費報告）在目前覆蓋該公司的五家研究機構中獲得了 “買入” 的平均推薦，Marketbeat.com 報道。一位研究分析師對該股票給予了賣出評級，兩位給予了買入評級，兩位給予了強烈買入評級。在過去一年中更新了對該股票覆蓋的經紀公司中，12 個月的平均目標價為 169.00 美元。</p>
</div><p>A number of equities analysts recently issued reports on ICUI shares. Jefferies Financial Group upgraded ICU Medical to a &#34;strong-buy&#34; rating in a report on Thursday. Piper Sandler decreased their target price on ICU Medical from $178.00 to $163.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, April 17th. Wall Street Zen cut ICU Medical from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, April 18th. KeyCorp decreased their target price on ICU Medical from $180.00 to $164.00 and set an &#34;overweight&#34; rating on the stock in a report on Monday, April 27th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of ICU Medical in a report on Thursday, January 22nd.</p>
<div class="lb-trans"><p>一些股票分析師最近對 ICUI 股票發佈了報告。傑富瑞金融集團在週四的報告中將 ICU Medical 的評級上調至 “強烈買入”。派珀·桑德勒在 4 月 17 日的報告中將 ICU Medical 的目標價從 178.00 美元下調至 163.00 美元，並對該股票給予了 “超配” 評級。華爾街 Zen 在 4 月 18 日的報告中將 ICU Medical 的評級從 “買入” 下調至 “持有”。KeyCorp 在 4 月 27 日的報告中將 ICU Medical 的目標價從 180.00 美元下調至 164.00 美元，並對該股票給予了 “超配” 評級。最後，Weiss Ratings 在 1 月 22 日的報告中重申了對 ICU Medical 股票的 “賣出（d-）” 評級。</p>
</div><p><strong>Get Our Latest Report on ICUI</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 ICUI 的最新報告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the business. Bryce Point Capital LLC purchased a new position in shares of ICU Medical during the third quarter valued at $586,000. Inscription Capital LLC grew its holdings in shares of ICU Medical by 407.9% during the third quarter. Inscription Capital LLC now owns 8,365 shares of the medical instruments supplier's stock valued at $1,003,000 after buying an additional 6,718 shares in the last quarter. Federated Hermes Inc. grew its holdings in shares of ICU Medical by 56.5% during the third quarter. Federated Hermes Inc. now owns 290,292 shares of the medical instruments supplier's stock valued at $34,823,000 after buying an additional 104,798 shares in the last quarter. Emerald Mutual Fund Advisers Trust purchased a new position in shares of ICU Medical during the third quarter valued at $1,096,000. Finally, Schroder Investment Management Group grew its holdings in shares of ICU Medical by 25.2% during the third quarter. Schroder Investment Management Group now owns 796,704 shares of the medical instruments supplier's stock valued at $93,246,000 after buying an additional 160,380 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近修改了對該公司的持股。Bryce Point Capital LLC 在第三季度購買了 ICU Medical 股票的新頭寸，價值 586,000 美元。Inscription Capital LLC 在第三季度將其在 ICU Medical 的持股增加了 407.9%。Inscription Capital LLC 現在擁有 8,365 股該醫療器械供應商的股票，價值 1,003,000 美元，在上個季度又購買了 6,718 股。Federated Hermes Inc.在第三季度將其在 ICU Medical 的持股增加了 56.5%。Federated Hermes Inc.現在擁有 290,292 股該醫療器械供應商的股票，價值 34,823,000 美元，在上個季度又購買了 104,798 股。Emerald Mutual Fund Advisers Trust 在第三季度購買了 ICU Medical 股票的新頭寸，價值 1,096,000 美元。最後，施羅德投資管理集團在第三季度將其在 ICU Medical 的持股增加了 25.2%。施羅德投資管理集團現在擁有 796,704 股該醫療器械供應商的股票，價值 93,246,000 美元，在上個季度又購買了 160,380 股。對沖基金和其他機構投資者持有該公司 96.10% 的股票。</p>
</div><h2>Key ICU Medical News</h2>
<div class="lb-trans"><h2>ICU Medical 的關鍵新聞</h2>
</div><p>Here are the key news stories impacting ICU Medical this week:</p>
<div class="lb-trans"><p>以下是本週影響 ICU Medical 的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: Q1 earnings beat — ICU reported $1.97 EPS vs. $1.78 consensus and revenue of $525.8M above estimates, showing an operational beat that typically supports the stock. ICU Medical (ICUI) Tops Q1 Earnings and Revenue Estimates</li>
<li>Positive Sentiment: FY2026 guidance nudged slightly above street expectations (EPS guide of $7.75–$8.45 vs. consensus ~7.74), which reduces downside risk to forward earnings and supports multiple expansion. ICU Medical Announces First Quarter 2026 Results</li>
<li>Positive Sentiment: Analyst support — Jefferies upgraded ICU to &#34;strong-buy&#34; and Piper Sandler reaffirmed its buy rating, bringing additional buy-side attention that can lift the stock. Jefferies upgrade / coverage notePiper Sandler Reaffirms Buy</li>
<li>Neutral Sentiment: Investor materials available — the company released its slide deck and earnings presentation, useful for digging into segment trends and margin drivers but not an immediate price catalyst by itself. Earnings Call Presentation</li>
<li>Negative Sentiment: Revenue and margin pressure — revenue was down ~12–14% year-over-year and the reported net margin remains very thin, which raises questions about growth trajectory and earnings quality despite the EPS beat. Quarterly results and transcript</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：第一季度收益超出預期——ICU 報告每股收益 1.97 美元，超過 1.78 美元的共識預期，收入為 5.258 億美元，超出預期，顯示出運營上的超出，通常會支持股票。ICU Medical（ICUI）第一季度收益和收入超出預期</li>
<li>積極情緒：2026 財年指引略微高於市場預期（每股收益指引為 7.75–8.45 美元，而共識約為 7.74），這降低了未來收益的下行風險，並支持估值擴張。ICU Medical 公佈 2026 年第一季度業績</li>
<li>積極情緒：分析師支持——傑富瑞將 ICU 評級上調至 “強烈買入”，派珀·桑德勒重申其買入評級，帶來了額外的買方關注，可能會提升股票。傑富瑞升級/覆蓋説明派珀·桑德勒重申買入</li>
<li>中性情緒：投資者材料可用——公司發佈了其幻燈片和收益演示，便於深入瞭解細分趨勢和利潤驅動因素，但本身並不是立即的價格催化劑。收益電話會議演示</li>
<li>消極情緒：收入和利潤壓力——收入同比下降約 12-14%，報告的淨利潤率仍然非常薄弱，這引發了對增長軌跡和收益質量的質疑，儘管每股收益超出預期。季度業績和會議記錄</li>
</ul>
</div><h2>ICU Medical Stock Performance</h2>
<div class="lb-trans"><h2>ICU Medical 股票表現</h2>
</div><p>Shares of NASDAQ ICUI opened at $123.07 on Friday. The company has a quick ratio of 1.15, a current ratio of 2.39 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of 6,156.58, a PEG ratio of 1.72 and a beta of 0.74. The stock's fifty day simple moving average is $128.93 and its 200 day simple moving average is $138.35. ICU Medical has a 52-week low of $107.00 and a 52-week high of $160.29.</p>
<div class="lb-trans"><p>納斯達克 ICUI 的股票在週五開盤價為 123.07 美元。該公司的速動比率為 1.15，流動比率為 2.39，債務與股本比率為 0.60。該股票的市值為 30.8 億美元，市盈率為 6,156.58，PEG 比率為 1.72，貝塔值為 0.74。該股票的 50 日簡單移動平均線為 128.93 美元，200 日簡單移動平均線為 138.35 美元。ICU Medical 的 52 周低點為 107.00 美元，52 周高點為 160.29 美元。</p>
</div><p>ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.68 by $0.23. The business had revenue of $535.94 million for the quarter, compared to analysts' expectations of $541.20 million. ICU Medical had a return on equity of 7.33% and a net margin of 0.03%.The company's quarterly revenue was down 14.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.11 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, sell-side analysts forecast that ICU Medical will post 6.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>ICU Medical（納斯達克代碼：ICUI - 獲取免費報告）最後一次發佈其收益結果是在 2 月 19 日，星期四。該醫療器械供應商報告本季度每股收益（EPS）為 1.91 美元，超過分析師共識預期的 1.68 美元，超出 0.23 美元。該公司本季度的收入為 5.3594 億美元，而分析師的預期為 5.4120 億美元。ICU Medical 的股本回報率為 7.33%，淨利潤率為 0.03%。該公司的季度收入同比下降 14.1%。在前一年同期，該公司發佈的每股收益為 2.11 美元。ICU Medical 已將其 2026 財年的指引設定為每股收益 7.750-8.450 美元。作為一個整體，賣方分析師預測 ICU Medical 在當前財年將發佈每股收益 6.31 美元。</p>
</div><h2>ICU Medical Company Profile</h2>
<div class="lb-trans"><h2>ICU Medical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.</p>
<div class="lb-trans"><p>ICU Medical, Inc 及其子公司開發、製造和銷售用於輸液治療、血管通路和生命監護應用的醫療設備。其輸液治療產品包括 MicroClave、MicroClave Clear 和 NanoClave 品牌的無針產品；Neutron 導管通暢設備；ChemoClave 和 ChemoLock 封閉系統轉移設備，用於限制有害藥物或蒸汽濃度的逸出，阻止環境污染物進入系統，並消除針刺傷害的風險；Tego 無針連接器；Deltec GRIPPER 非穿刺針用於門靜脈通路；以及 ClearGuard、SwabCap 和 SwabTip 消毒蓋。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than ICU Medical</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 ICU Medical</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUNVSQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ICUI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何關於此故事的問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ICU Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 ICU Medical 嗎？</h2>
</div><p>Before you consider ICU Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 ICU Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 ICU Medical 並不在名單上。</p>
</div><p>While ICU Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ICU Medical 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

ICU Medical, Inc. (NASDAQ:ICUI) Given Average Rating of "Buy" by Analysts

Market Beat

Jefferies Financial

Piper Sandler Cos

科凱國際

Federated Hermes

施羅德投資集團

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

ICU 醫療公司（納斯達克股票代碼：ICUI）被分析師給予 “買入” 的平均評級